What is ARS Pharmaceuticals, Inc.'s revenue?

ARS Pharmaceuticals, Inc. (SPRY) generated $99.0M in revenue over the trailing twelve months, up 1.9% year over year.

Is ARS Pharmaceuticals, Inc. profitable?

ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $198.0M over the trailing twelve months, a -200.0% net margin.

What is ARS Pharmaceuticals, Inc.'s earnings per share?

ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.01.

Where does ARS Pharmaceuticals, Inc.'s income statement data come from?

Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ARS Pharmaceuticals, Inc. SPRY Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$84.28M-5.5%	$89.15M+297,063%	$30K-97.7%	$1.32M-76.1%
Research and development	$13.18M-32.7%	$19.58M-3.4%	$20.27M+10.3%	$18.38M—
Selling, general and administrative	$230.12M+221%	$71.68M—	——	——
Other operating expenses	$263.73M+186%	$92.23M+36.5%	$67.55M+83.4%	$36.83M—
Total operating expenses	$263.73M+186%	$92.23M+36.5%	$67.55M+83.4%	$36.83M—
Operating income	-$179.45M—	——	-$67.52M-90.1%	-$35.52M—
Operating margin	-212.9%—	——	-225,066.7%-222,368pp	-2,698.8%—
Other income (expense), net	$8.07M-29.0%	$11.37M-13.6%	$13.16M+1,477%	$834K+206%
Income before income taxes	-$171.38M-2,168%	$8.29M+115%	-$54.37M—	——
Income tax expense	-$80K-128%	$288K—	$0—	——
Net income	-$171.3M-2,242%	$8M+115%	-$54.37M-56.8%	-$34.68M—
Net margin	-203.3%-212pp	9%+181,226pp	-181,216.7%-178,581pp	-2,635.4%—
Diluted earnings per share	-$1.75-2,600%	$0.07+112%	-$0.57+34.5%	-$0.87—
Basic earnings per share	-$1.75-2,600%	$0.07+112%	-$0.57+34.5%	-$0.87—
Weighted-average shares, diluted	393.8M+0.3%	392.7M+3.4%	379.9M+189%	131.7M-1.4%
Weighted-average shares, basic	393.8M+1.7%	387.3M+1.9%	379.9M+189%	131.7M—
Cost Of Goods Sold Operating Expense	$20.42M+1,990%	$977K—	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$171.39M-2,198%	$8.17M+115%	-$54.72M-59.7%	-$34.28M—
Net unrealized gains (losses) on securities still held	——	——	——	$407K—
Other Nonoperating Expense	——	$0—	——	——
Other Nonoperating Income	——	$11.37M—	——	——
Other income, net (Note 6)	$8.07M-29.0%	$11.37M-13.6%	$13.16M+1,251%	$974K+223%
Revenue From Contract With Customer Excluding Assessed Tax	$84.28M-5.5%	$89.15M+297,063%	$30K-97.7%	$1.32M-76.1%
EBIT	-$179.45M-272%	-$48.21M+28.6%	-$67.52M-90.1%	-$35.52M—
EBITDA	-$178.08M-270%	-$48.13M+28.6%	-$67.45M-92.3%	-$35.07M—
EBITDA	-$178.08M-270%	-$48.13M+28.6%	-$67.45M-92.3%	-$35.07M—
EBITDA margin	-211.3%-157pp	-54%+224,769pp	-224,823.3%-222,158pp	-2,664.9%—
EBIT	-$179.45M-272%	-$48.21M+28.6%	-$67.52M-90.1%	-$35.52M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about ARS Pharmaceuticals, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s revenue?: ARS Pharmaceuticals, Inc. (SPRY) generated $99.0M in revenue over the trailing twelve months, up 1.9% year over year.
Is ARS Pharmaceuticals, Inc. profitable?: ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $198.0M over the trailing twelve months, a -200.0% net margin.
What is ARS Pharmaceuticals, Inc.'s earnings per share?: ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.01.
Where does ARS Pharmaceuticals, Inc.'s income statement data come from?: Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.